Selected article for: "vast majority and wild type"
Author: Avirutnan, Panisadee; Hauhart, Richard E.; Marovich, Mary A.; Garred, Peter; Atkinson, John P.; Diamond, Michael S.
Title: Complement-Mediated Neutralization of Dengue Virus Requires Mannose-Binding Lectin
  • Document date: 2011_12_13
    • ID: 1x3n5job_22
    Snippet: creased risk of DENV-induced thrombocytopenia with wild-type but not low-producer MBL genotypes (45) , another found no effect of MBL variation on the risk of severe dengue infection (46) . However, the vast majority of patients from these studies were experiencing secondary dengue infection, when cross-reactive complement-fixing antibodies are present. MBL opsonization could protect against primary DENV infection (when anti-DENV antibodies are a.....
    Document: creased risk of DENV-induced thrombocytopenia with wild-type but not low-producer MBL genotypes (45) , another found no effect of MBL variation on the risk of severe dengue infection (46) . However, the vast majority of patients from these studies were experiencing secondary dengue infection, when cross-reactive complement-fixing antibodies are present. MBL opsonization could protect against primary DENV infection (when anti-DENV antibodies are absent or at low levels) yet be overshadowed during secondary DENV infection when antibody-mediated classical pathway-dependent complement activation occurs. At present, it is poorly understood why the majority (up to almost 90% in some studies) of primary DENV infections are asymptomatic (47) (48) (49) .

    Search related documents:
    Co phrase search for related documents
    • anti denv antibody and wild type: 1
    • classical pathway dependent complement activation and complement activation: 1, 2
    • classical pathway dependent complement activation and pathway dependent complement activation: 1, 2
    • complement activation and dengue infection: 1
    • complement activation and DENV infection: 1, 2, 3, 4, 5
    • complement activation and low level: 1, 2, 3
    • complement activation and MBL genotype: 1
    • complement activation and MBL opsonization: 1
    • complement activation and MBL variation: 1, 2
    • complement activation and pathway dependent complement activation: 1, 2
    • complement activation and secondary DENV infection: 1
    • complement activation and study patient: 1, 2
    • complement activation and wild type: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15